WDFY3 Antibody

What is WDFY3 and what are its key structural features?

WDFY3 (WD repeat and FYVE domain containing 3), also known as ALFY (Autophagy-Linked FYVE protein), is a large protein with a molecular weight of approximately 395 kDa comprising 3,526 amino acids in humans . Structurally, WDFY3 contains one BEACH domain, one FYVE-type zinc finger, a pair of leucine-rich repeats, and five WD repeats that participate in diverse cellular functions including chromatin assembly, cell cycle control, and signal transduction . It predominantly localizes to the cytoplasmic side of peripheral membranes, where it colocalizes with autophagic structures, particularly in nutrient-starved cells . WDFY3 is also found in the nucleus and cytoplasm, suggesting multiple functional roles depending on cellular context .

What types of WDFY3 antibodies are available for research applications?

Several types of WDFY3 antibodies are available for research applications, varying in host species, clonality, and applications:

When selecting an antibody, consider both the specific application needs and the target species to ensure optimal experimental results .

How does WDFY3 function in autophagy and cellular homeostasis?

WDFY3 serves as an adapter protein in selective macroautophagy (aggrephagy), linking proteins destined for degradation to core autophagic machinery components including ATG5-ATG12-ATG16L E3-like ligase, SQSTM1 (p62), and LC3 . WDFY3 plays a critical role in the formation and autophagic degradation of cytoplasmic ubiquitin-containing inclusions (p62 bodies or aggresome-like induced structures) . It shuttles from the nuclear membrane to colocalize with aggregated proteins, where it complexes with other autophagic components to facilitate macroautophagy-mediated clearance . Notably, while essential for selective autophagy of protein aggregates, WDFY3 is not required for starvation-induced macroautophagy . Recent research also highlights WDFY3's role in midbody remnant degradation after cytokinetic abscission , demonstrating its versatile functions in maintaining cellular homeostasis.

What are the optimal conditions for using WDFY3 antibodies in immunohistochemistry (IHC)?

Successful immunohistochemical detection of WDFY3 requires careful optimization of antigen retrieval and antibody dilution protocols:

For optimal results, each antibody should be validated in your specific experimental system as reactivity can vary between tissue types and fixation methods . When analyzing brain samples, be aware that WDFY3 is abundantly expressed in neuronal cells where it regulates the clearance of aggregated proteins through aggrephagy .

How can WDFY3 function be studied in macrophage efferocytosis models?

Studying WDFY3's role in macrophage efferocytosis requires specialized experimental approaches:

• Cell Culture Systems: Use bone marrow-derived macrophages (BMDMs) from control or WDFY3-knockout/overexpressing mice .

• Efferocytosis Assay: Challenge macrophages with apoptotic cells (ACs) and measure engulfment efficiency using flow cytometry or microscopy techniques .

• Molecular Readouts:

  • Analyze inflammasome activation by measuring IL-1β secretion and caspase-1 cleavage in macrophages

  • Assess T cell activation using standard antigen presentation assays with OVA-treated macrophages and T cells from OT-II or OT-I transgenic mice

  • Examine MHC-II mediated antigen presentation capacity

• In Vivo Models:

  • Systematically inject ACs in young mice to increase AC burden

  • Study middle-aged mice for spontaneous autoimmunity development

  • Use myeloid-specific knockout mice (Wdfy3 deficient) or whole-body overexpression mice (hWDFY3 KI/KI)

• Autoimmunity Markers:

  • Measure circulating autoantibodies (ANA, anti-dsDNA)

  • Assess organ damage markers and examine kidney histology for glomeruli size and immunocomplex deposition (C1q, IgG)

These approaches have revealed that WDFY3 enhances efferocytosis, suppresses AC-induced inflammasome activation, and mitigates T cell activation, thereby protecting against autoimmunity .

What approaches can be used to validate WDFY3 antibody specificity?

Validating WDFY3 antibody specificity is essential for generating reliable data, especially given the protein's large size and multiple isoforms:

• Knockout/Knockdown Controls: Use WDFY3 knockout or knockdown samples as negative controls—the specific band or signal should be absent or significantly reduced .

• Overexpression Systems: Complementary to knockout controls, overexpression systems can confirm that increased WDFY3 expression correlates with increased signal intensity .

• Cross-Species Reactivity Testing: Verify antibody performance across multiple species if conducting comparative studies—reactivity can vary between human, mouse, and rat samples .

• Multiple Antibody Approach: Use antibodies targeting different epitopes of WDFY3 to confirm consistent detection patterns .

• Alternative Splicing Awareness: Be aware that WDFY3 has multiple splice variants—for example, a 50kDa band in Western blot represents a specific splicing form of WDFY3 .

• Non-specific Binding Assessment: Include appropriate blocking steps and isotype controls to minimize background and non-specific binding.

Proper validation ensures that experimental observations truly reflect WDFY3 biology rather than artifacts of non-specific antibody interactions.

How do WDFY3 expression patterns correlate with autoimmune phenotypes?

Recent research has established significant correlations between WDFY3 expression and autoimmune manifestations:

RNA-seq analysis of WDFY3-overexpressing macrophages revealed minimal transcriptomic changes (only 13 differentially expressed genes), suggesting that WDFY3's protective effects against autoimmunity operate primarily through post-transcriptional mechanisms . The primary protective mechanisms include enhanced clearance of apoptotic cells (limiting autoantigen availability), suppression of inflammasome activation (reduced IL-1β and IL-18 production), and decreased MHC-II-mediated antigen presentation to T cells .

What is the relationship between WDFY3, autophagy, and neurodevelopmental disorders?

WDFY3 plays crucial roles in brain development and neurological function:

• Axonal Tract Formation: WDFY3 is essential for forming axonal tracts throughout the brain and spinal cord, including major forebrain commissures .

• Neuronal Guidance: It mediates the ability of neural cells to respond to guidance cues, including the trophic effects of netrin-1/NTN1 .

• Wnt Signaling Regulation: WDFY3 regulates Wnt signaling by removing DVL3 aggregates through autophagy-dependent mechanisms, which appears important for determining brain size during embryonic development .

• Microcephaly Association: The WDFY3 gene has been associated with microcephaly (MCPH18), highlighting its importance in proper brain development .

• Neuroprotective Effects: Ectopic overexpression of WDFY3 exerts neuroprotective effects in mouse models, likely through enhanced clearance of protein aggregates .

These findings suggest that studying WDFY3 function using specific antibodies may provide insights into the pathogenesis of neurodevelopmental disorders and potential therapeutic approaches for conditions involving neuronal protein aggregation.

How can WDFY3 antibodies be used to investigate inflammasome regulation?

WDFY3 antibodies provide valuable tools for investigating inflammasome regulation in various contexts:

• Protein Interaction Studies: Co-immunoprecipitation with WDFY3 antibodies can identify protein interactions between WDFY3 and inflammasome components .

• Subcellular Localization Analysis: Immunofluorescence microscopy using WDFY3 antibodies can reveal co-localization patterns with inflammasome components in different cellular compartments .

• Expression Correlation Studies: Western blot analysis using WDFY3 antibodies alongside inflammasome markers (pro-IL-1β, cleaved caspase-1) can establish correlations between WDFY3 expression and inflammasome activation status .

• Functional Assessments: Use WDFY3 antibodies to track protein expression in experimental models where inflammasome activity is assessed (e.g., IL-1β and IL-18 secretion assays) .

Recent research demonstrated that WDFY3 overexpression suppresses apoptotic cell-induced inflammasome activation, resulting in decreased pro-IL-1β expression, reduced caspase-1 cleavage, and lower IL-1β and IL-18 secretion . These findings suggest that WDFY3 may regulate inflammasome activation through macroautophagy-dependent degradation mechanisms, as macroautophagy has been implicated in NLRP3 inflammasome regulation .

What are common challenges in detecting WDFY3 and how can they be addressed?

Detecting WDFY3 presents several technical challenges that require specific troubleshooting approaches:

Additionally, when performing immunohistochemistry, background staining can be minimized by optimizing blocking conditions and incubation times. For WDFY3 detection in brain tissue, which shows particularly high expression, lower antibody concentrations may be necessary to avoid signal saturation .

How should researchers interpret conflicting WDFY3 data across different experimental systems?

When faced with conflicting WDFY3 data across experimental systems, consider these analytical approaches:

• Species-Specific Differences: WDFY3 function may vary between human, mouse, and rat models. Confirm antibody cross-reactivity and be cautious when extrapolating findings across species .

• Cell Type Considerations: WDFY3 is abundantly expressed in neuronal cells and macrophages but expression levels and functions may differ in other cell types. Context-specific roles should be considered when interpreting data .

• Splice Variant Analysis: Multiple alternatively spliced transcript variants exist for WDFY3, and their full-length nature is not always defined. Different experimental systems may express different isoforms, leading to apparently conflicting results .

• Autophagy Status: WDFY3 function is linked to selective autophagy but not starvation-induced autophagy. The autophagy status of experimental systems (basal vs. induced) should be considered when comparing results .

• Developmental Stage Effects: WDFY3's role in brain development suggests age-dependent functions. Comparing data from different developmental stages requires careful consideration of these temporal effects .

• Compensation Mechanisms: In knockout models, especially those with constitutive deletions, compensatory mechanisms may mask phenotypes that would be observed with acute depletion approaches .

By systematically evaluating these factors, researchers can better interpret seemingly conflicting WDFY3 data and develop more refined hypotheses for further investigation.

What considerations are important when designing experiments to study WDFY3 in efferocytosis?

When designing experiments to study WDFY3 in efferocytosis, researchers should consider:

• Apoptotic Cell Preparation: Standardize methods for generating apoptotic cells (UV irradiation, staurosporine treatment, etc.) and verify apoptosis status using multiple markers (Annexin V, propidium iodide) .

• Macrophage Source and Polarization: Bone marrow-derived macrophages (BMDMs) are commonly used, but source (bone marrow vs. peritoneal vs. cell lines) and polarization state (M1 vs. M2) can significantly impact efferocytosis efficiency .

• Quantification Methods: Develop robust quantification methods for efferocytosis, such as:

  • Flow cytometry (labeling apoptotic cells with pH-sensitive dyes)

  • Microscopy with z-stack imaging to confirm internalization

  • Time-lapse imaging to capture dynamics

• Genetic Manipulation Strategies: Consider:

  • Constitutive vs. inducible knockout models

  • Cell-specific (myeloid-restricted) vs. global manipulation

  • Acute (siRNA) vs. stable (CRISPR) manipulation approaches

• Downstream Pathway Analysis: Include readouts for:

  • Inflammasome activation (IL-1β, caspase-1 cleavage)

  • Antigen presentation (MHC-II levels, T cell activation)

  • Anti-inflammatory cytokine production (TGF-β, IL-10)

• In Vivo Translation: Design in vivo models that reflect physiological efferocytosis challenges:

  • Systemic apoptotic cell injection

  • Age-associated spontaneous autoimmunity

  • Tissue-specific injury models

By carefully addressing these considerations, researchers can design more rigorous experiments to elucidate WDFY3's role in efferocytosis and its implications for autoimmune disorders.

What therapeutic applications could emerge from WDFY3 research?

Research on WDFY3 suggests several promising therapeutic applications:

• Autoimmune Disease Management: Enhancing WDFY3 expression or activity could potentially mitigate autoimmune disorders by improving efferocytosis efficiency, reducing autoantigen availability, and suppressing inflammasome activation .

• Neurodegenerative Disease Treatment: Given WDFY3's role in clearing protein aggregates through aggrephagy, targeting WDFY3 pathways might benefit conditions characterized by protein aggregation, such as Alzheimer's and Parkinson's diseases .

• Microcephaly and Neurodevelopmental Disorders: Understanding WDFY3's role in brain development and Wnt signaling may lead to interventions for WDFY3-associated microcephaly (MCPH18) and related neurodevelopmental conditions .

• Age-Associated Inflammation: WDFY3 overexpression protected against age-associated chronic inflammation in middle-aged mice, suggesting potential applications in addressing inflammaging .

• Cancer Immunotherapy: WDFY3's involvement in efferocytosis and antigen presentation might be leveraged to modulate tumor-associated macrophage function in the cancer microenvironment .

Development of these therapeutic applications would require advanced tools for manipulating WDFY3 expression or function, such as small molecule enhancers, gene therapy approaches, or targeted delivery systems for WDFY3-modulating compounds.

What are the key unresolved questions regarding WDFY3 function in cellular homeostasis?

Despite significant advances, several critical questions about WDFY3 remain unresolved:

• Regulatory Mechanisms: How is WDFY3 expression and activity regulated under different physiological and pathological conditions? What signaling pathways control its subcellular localization and function?

• Selective Substrate Recognition: How does WDFY3 specifically recognize aggregated proteins and apoptotic cells for clearance while sparing other cellular components?

• Isoform-Specific Functions: What are the distinct roles of different WDFY3 splice variants, and how do they contribute to tissue-specific functions?

• Interaction Network: What is the complete interactome of WDFY3 in different cellular contexts, and how do these interactions mediate its diverse functions?

• Evolutionary Conservation: How conserved are WDFY3 functions across species, and what does this reveal about fundamental cellular processes?

• Therapeutic Modulation: Can WDFY3 function be selectively enhanced in specific tissues without disrupting its normal role in other cellular contexts?

• Crosstalk with Other Pathways: How does WDFY3-mediated aggrephagy and efferocytosis interact with other cellular quality control and immune regulatory pathways?

• Temporal Dynamics: What are the kinetics of WDFY3 recruitment and action during autophagy and efferocytosis, and how is this timing regulated?